Uncategorized
ThromboGenics regains full global rights to Jetrea
ThromboGenics has regained full global rights to Jetrea from Alcon, according to a press release.Under the terms of the deal, ThromboGenics will receive 53.7 million euros in cash and an equity investment of 10 million euros in ThromboGenics capital.